BioCentury
ARTICLE | Clinical News

Ibrance palbociclib: Phase III started

September 14, 2015 7:00 AM UTC

Pfizer began the open-label, international Phase III PALLAS trial to compare 125 mg oral Ibrance once daily for the first 21 days of each 28-day cycle for 2 years plus standard endocrine adjuvant therapy for >=5 years vs. endocrine adjuvant therapy in about 4,600 patients. Pfizer is conducting the trial in collaboration with the Alliance Foundation Trials LLC, the Austrian Breast & Colorectal Cancer Study Group (ABCSG), the Breast International Group, the German Breast Group (GBG), the National Surgical Adjuvant Breast and Bowel Project (NSABP) and PrECOG LLC. ...